AstraZeneca drug approved in US to reduce risk of heart failure in type-2 diabetes patients

Writer,

AstraZeneca said its type-2 diabetes drug was approved by US regulators to reduce the risk of hospitalisation for heart failure in adults with type-2 diabetes and established cardiovascular disease.

The approval comes on the back of results from the Declare-Timi 58 cardiovascular outcomes trial (CVOT), to evaluate type-2 diabetes (T2D) patients with multiple CV risk factors or established CV disease.

'This is promising news for the 30 million people living with type-2 diabetes in the US, as heart failure is one of the earliest cardiovascular complications for them, before heart attack or stroke. Farxiga now offers the opportunity for physicians to act sooner and reduce the risk of hospitalisation for heart failure,' said Ruud Dobber, Executive Vice President, BioPharmaceuticals Business Unit.


Related content

Broker Forecast - UBS issues a broker note on AstraZeneca PLC

UBS today reaffirms its sell investment rating on AstraZeneca PLC (LON:AZN) and raised its price target to 7300p (from 6000p).

Broker Forecasts data provided by...

Thu, 04/06/2020 - 11:40


Broker Forecast - Bryan Garnier issues a broker note on AstraZeneca PLC

Bryan Garnier today reaffirms its buy investment rating on AstraZeneca PLC (LON:AZN) and raised its price target to 9100p (from 8780p).

Broker Forecasts data provided...

Tue, 02/06/2020 - 10:10


AstraZeneca cancer drug wins marketing approval in US; heart disease treatment approved in US

Pharma giant AstraZeneca said its cancer drug had been recommended for marketing authorisation in the European Union to treat patients with metastatic pancreatic cancer.

The...

Mon, 01/06/2020 - 07:37


AstraZeneca, Daiichi Sankyo report positive trial results for gastric cancer drug

Pharmaceutical company AstraZeneca said a venture with Daiichi Sankyo had recorded positive clinical trial results for a gastric cancer treatment.

The trial showed that the...

Fri, 29/05/2020 - 14:56


AstraZeneca lung cancer drug cuts risk of disease recurrence or death by about 80%

Pharma giant AstraZeneca said a clinical trial of a drug to treat non-small cell lung cancer reduced the risk of disease recurrence or death by...

Fri, 29/05/2020 - 08:09